13F Holdings
中文EN

RANI Rani Therapeutics Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1856725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY448.7%
TTM net income YoY-14.6%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-530.5%
Net margin-493.0%
FCF margin-352.7%
EBITDA margin-520.6%

Returns

ROE-248.6%
ROA-103.6%
ROIC (approx.)-173.1%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets21.3%
Debt / equity0.00x
Current ratio5.26x
Interest coverage-71.86x

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-30.2%
Payout ratio—
Capex / revenue3.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.63M$1.03M$0$0$2.72M
R&D expense$20.20M$26.68M$39.62M$36.61M$26.48M
SG&A expense$19.74M$23.95M$26.48M$26.84M$27.83M
Operating income-$38.31M-$53.31M-$66.10M-$63.45M-$51.60M
Interest expense$2.89M$5.03M$5.08M$1.07M$466,000
Pretax income——-$67.88M-$63.27M-$53.05M
Income tax$0$0$0$70,000$41,000
Net income-$29.67M-$30.02M-$33.97M-$30.59M-$8.33M
EBITDA-$37.41M-$52.29M-$65.28M-$62.90M-$51.10M
EPS (basic)-0.45-1.05-1.33-1.28-0.43
EPS (diluted)-0.45-1.05-1.33-1.28-0.43
Weighted avg. shares (diluted)66,13828,47625,50523,81719,534
Balance sheet
Cash & equivalents$18.62M$4.26M$6.36M$27.51M$117.45M
Short-term investments———$98.50M—
Receivables$2.04M$0———
Current assets$53.32M$29.74M$50.85M$100.92M$119.59M
PP&E, net$736,000$1.55M$6.11M$6.04M$4.61M
Total assets$58.62M$36.63M$57.92M$108.03M$124.21M
Current liabilities$12.67M$19.89M$7.99M$4.82M$2.64M
Short-term debt$0$15.00M$4.90M$0—
Long-term debt$0$9.61M$24.48M$29.15M$0
Total debt$0$24.61M$29.38M$29.15M$0
Total liabilities$17.11M$33.14M$32.47M$34.02M$2.64M
Shareholders' equity$33.01M$1.99M$12.87M$36.85M$47.41M
Net debt-$18.62M$20.35M$23.02M$1.64M-$117.45M
Cash flow statement
Operating cash flow-$18.71M-$35.50M-$51.24M-$46.52M-$32.24M
Capital expenditure$88,000$268,000$1.23M$1.62M$506,000
Free cash flow-$18.80M-$35.76M-$52.47M-$48.13M-$32.75M
Investing cash flow-$7.03M$19.81M$29.86M-$72.44M-$506,000
Financing cash flow$40.30M$13.59M$233,000$29.00M$77.15M
Depreciation & amortization$900,000$1.03M$822,000$548,000$497,000
Stock-based compensation$11.80M$16.03M$19.01M$15.78M$22.59M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.